G
Giovanni Cazzaniga
Researcher at University of Milano-Bicocca
Publications - 297
Citations - 18435
Giovanni Cazzaniga is an academic researcher from University of Milano-Bicocca. The author has contributed to research in topics: Minimal residual disease & Leukemia. The author has an hindex of 63, co-authored 264 publications receiving 16108 citations. Previous affiliations of Giovanni Cazzaniga include Duke University & Hannover Medical School.
Papers
More filters
Journal ArticleDOI
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
Jean Gabert,Emmanuel Beillard,V H J van der Velden,Wanli Bi,David Grimwade,Niels Pallisgaard,Gisela Barbany,Giovanni Cazzaniga,Jean Michel Cayuela,Hélène Cavé,Fabrizio Pane,J. L. E. Aerts,D De Micheli,X Thirion,V Pradel,Marcos González,Susanne Viehmann,Maria Malec,Giuseppe Saglio,J. J. M. Van Dongen +19 more
TL;DR: The development of standardized protocols for RQ-PCR analysis of FG transcripts provides a milestone for molecular determination of MRD levels and is likely to prove invaluable to the management of patients entered into multicenter therapeutic trials.
Journal ArticleDOI
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
Jacques J.M. van Dongen,T Seriu,E. Renate Panzer-Grümayer,Andrea Biondi,M. J. Pongers-Willemse,Lilly Corral,Frank Stolz,Martin Schrappe,Giuseppe Masera,Willem Kamps,Helmuth Gadner,Elisabeth R. van Wering,Wolf-Dieter Ludwig,Giuseppe Basso,Marianne Ac de Bruijn,Giovanni Cazzaniga,Klaudia Hettinger,Anna van der Does-van den Berg,Wim C. J. Hop,Hansjörg Riehm,Claus R. Bartram +20 more
TL;DR: Monitoring patients with childhood ALL at consecutive time points gives clinically relevant insight into the effectiveness of treatment, and combined information on MRD from the first 3 months of treatment distinguishes patients with good prognoses from those with poor prognose, and this helps in decisions whether and how to modify treatment.
Journal ArticleDOI
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Valentino Conter,Claus R. Bartram,Maria Grazia Valsecchi,André Schrauder,Renate Panzer-Grümayer,Anja Möricke,Maurizio Aricò,Martin Zimmermann,Georg Mann,Giulio Rossi,Martin Stanulla,Franco Locatelli,Giuseppe Basso,Felix Niggli,Elena Barisone,Guenter Henze,Wolf-Dieter Ludwig,Oskar A. Haas,Giovanni Cazzaniga,Rolf Koehler,Daniela Silvestri,Jutta Bradtke,Rosanna Parasole,Rita Beier,Jacques J.M. van Dongen,Andrea Biondi,Martin Schrappe +26 more
TL;DR: Standardized quantitative assessment of minimal residual disease based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD) at 2 time points (TPs) is introduced, to stratify patients in a large prospective study.
Journal ArticleDOI
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
V H J van der Velden,Giovanni Cazzaniga,André Schrauder,Jeremy Hancock,Peter Bader,E R Panzer-Grümayer,Thomas Flohr,Rosemary Sutton,Hélène Cavé,Hans O. Madsen,J M Cayuela,Jan Trka,Cornelia Eckert,Letizia Foroni,U zur Stadt,Kheira Beldjord,Thorsten Raff,C. E. Van Der Schoot,J. J. M. Van Dongen +18 more
TL;DR: The European Study Group on MRD detection in ALL (ESG-MRD-ALL), consisting of 30 MRD-PCR laboratories worldwide, has developed guidelines for the interpretation of real-time quantitative PCR-based MRD data.
Journal ArticleDOI
Prenatal origin of acute lymphoblastic leukaemia in children
Joseph L. Wiemels,Giovanni Cazzaniga,Maria Daniotti,Osborn B. Eden,G. M. Addison,Giuseppe Masera,Vaskar Saha,Andrea Biondi,Mel Greaves +8 more
TL;DR: The findings showed that childhood acute lymphoblastic leukaemia is frequently initiated by a chromosome translocation event in utero and that a postnatal promotional event is also required.